EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review

Missbrauch und Fehlgebrauch von Methylphenidat bei Patient:innen mit psychiatrischer Störung und Substanzgebrauchsstörung: systematische Übersicht

Stefania Chiappini, Pietro Domenico Gramuglia, Alessio Mosca, Clara Cavallotto, Andrea Miuli, John Martin Corkery, Amira Guirguis, Fabrizio Schifano, Giovanni Martinotti

Frontiers in Psychiatry · 18.11.2024 · 15

DOI: 10.3389/fpsyt.2024.1508732 ↗

Auf einen Blick

12 Studien zeigen ein erhöhtes Risiko für Fehlgebrauch von Methylphenidat bei Patient:innen mit psychiatrischen Störungen und Substanzgebrauchsstörung. Häufig genannt wurden höhere Dosen und nichtorale Anwendung.

Fragestellung

Wie häufig sind Missbrauch und Fehlgebrauch von Methylphenidat bei Patient:innen mit psychiatrischen Störungen und Substanzgebrauchsstörung, und welche Muster und Risiken werden beschrieben?

Methode

Systematische Übersicht nach PRISMA; Suche in PubMed und Scopus im August-September 2024; Screening nach Titel/Abstract und Volltext.

Ergebnisse

12 Studien. Fehlgebrauch wurde häufiger bei conduct disorder, mood disorder, anxiety disorder, personality disorder und major depression disorder berichtet. SUD mit Alcohol, Cannabis, Nicotine und Cocaine Use Disorder war ebenfalls mit höherem Risiko verbunden.

Schlussfolgerung der Autor:innen

Missbrauch und Fehlgebrauch von Methylphenidat sind bei Patient:innen mit psychiatrischen Störungen und SUD ein relevantes Problem. Die Autor:innen nennen integrierte Therapieansätze und strengere Verordnungskontrollen.

Kernaussagen

  • 12 eingeschlossene Studien
  • Erhöhtes Risiko bei psychiatrischen Störungen und SUD
  • Berichtet wurden auch gastrointestinale, kardiovaskuläre und psychotische Ereignisse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Psychiatry, online erschienen am 18.11.2024. Verfasst von Stefania Chiappini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Saint Camillus International University of Health Sciences, School of Medicine, Rome, Italy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methylphenidate (MPH), a central nervous system stimulant primarily prescribed for attention-deficit/hyperactivity disorder (ADHD), has seen increasing rates of misuse and abuse, particularly in patients with dual diagnosis (co-occurring psychiatric disorders and substance use disorders/SUDs). The heightened risk of dependence and adverse effects in these vulnerable populations warrants a systematic review to assess the prevalence and pattern of abuse/misuse of MPH among patients within this population and to understand potential risk factors, patterns of misuse, and outcomes, including the impact on psychiatric symptoms and overall mental health, the effects on SUD (e.g., exacerbation or mitigation of symptoms), and the incidence of adverse events and complications (e.g., cardiovascular issues, psychological effects). Methodology A systematic review was conducted in August-September 2024 using both PubMed and Scopus databases. The following search strategy was used: TITLE-ABS-KEY (methylphenidate OR Ritalin OR Concerta) AND TITLE-ABS-KEY (abuse OR misuse OR dependency OR addiction) AND TITLE-ABS-KEY (dual diagnosis OR comorbid psychiatric disorder OR psychiatric disorder AND substance use disorder). The systematic review was structured in accordance with the PRISMA guidelines and identified studies were assessed by title/abstract and full text screening against eligibility criteria.

Results

A total of 12 studies were selected for analysis after screening for relevance, quality, and adherence to inclusion criteria. Findings indicated that individuals with psychiatric disorders, particularly conduct disorder (N=593/1551 individuals), mood disorder (N=90/1551 individuals), anxiety disorder (N=66/1551 individuals), personality disorder (N=44/1551 individuals) and major depression disorder (N=40/1551 individuals), were more likely to misuse MPH. Co-occurring SUD, especially involving Alcohol Use Disorder (N=475/1551 individuals), Cannabis Use Disorder (N=371/1551 individuals), Nicotine Use Disorder (N=343/1551 individuals), Cocaine Use Disorder (N=68/1551 individuals), significantly elevated the risk. Misuse often involved higher doses than prescribed (N=84/1551 individuals) or using non-oral routes of administration (N=20/1551 individuals; e.g., snorting). Adverse outcomes included heightened risk of gastrointestinal events (N=201/1551 individuals), cardiovascular events (N=108/1551 individuals), psychosis (N=69/1551 individuals), and exacerbation of psychiatric symptoms (N=1082/1551 individuals).

Conclusion

MPH misuse and abuse are significant concerns in patients with psychiatric disorders and SUD. Risk factors include impulsivity, history of substance abuse, and access to prescription stimulants. Integrated therapeutic approaches and stricter prescription monitoring are recommended to mitigate misuse risks. Systematic review registration https://www.crd.york.ac.uk/prospero/, identifier CRD42024576724.

Schlagwörter

Stichwörter der Autor:innen

ADHDMPHSUDdrug misusedual diagnosismethylphenidatepharming

Autor:innen und Institutionen

  • Saint Camillus International University of Health Sciences, School of Medicine, Rome, Italy.
  • Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chieti, Italy.
  • Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
  • Swansea University Medical School, Swansea University, Swansea, United Kingdom.

Zitieren

APA

Chiappini, S., Gramuglia, P. D., Mosca, A., Cavallotto, C., Miuli, A., Corkery, J. M., Guirguis, A., Schifano, F., & Martinotti, G. (2024). Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1508732

Vancouver

Chiappini S, Gramuglia PD, Mosca A, Cavallotto C, Miuli A, Corkery JM, et al. Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. Frontiers in Psychiatry. 2024;15. doi:10.3389/fpsyt.2024.1508732

BibTeX
@article{Chiappini2024,
  author = {Chiappini, Stefania and Gramuglia, Pietro Domenico and Mosca, Alessio and Cavallotto, Clara and Miuli, Andrea and Corkery, John Martin and Guirguis, Amira and Schifano, Fabrizio and Martinotti, Giovanni},
  title = {Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review},
  journal = {Frontiers in Psychiatry},
  year = {2024},
  volume = {15},
  doi = {10.3389/fpsyt.2024.1508732}
}
Kostenlos starten →